Monte Rosa Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 17, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 17, 2026
GLUE$10.58+0.1%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated balance sheets
| December 31, | December 31, | |
|---|---|---|
| (in thousands, except share and per share amounts) | 2025 | 2024 |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $129,883 | $224,254 |
| Marketable securities | 247,221 | 147,895 |
| Collaboration receivable | 7,000 | — |
| Other receivables | 4,600 | 173 |
| Prepaid expenses and other current assets | 4,481 | 5,118 |
| Total current assets | 393,185 | 377,440 |
| Property and equipment, net | 25,986 | 29,483 |
| Operating lease right-of-use assets | 24,386 | 26,831 |
| Restricted cash | 4,954 | 4,863 |
| Other long-term assets | 148 | 115 |
| Total assets | $448,659 | $438,732 |
| Liabilities and stockholders’ equity | ||
| Current liabilities: | ||
| Accounts payable | $3,550 | $17,215 |
| Accrued expenses and other current liabilities | 26,694 | 18,785 |
| Current deferred revenue | 29,571 | 117,232 |
| Current portion of operating lease liability | 4,397 | 3,714 |
| Total current liabilities | 64,212 | 156,946 |
| Deferred revenue, net of current | 111,332 | 16,147 |
| Defined benefit plan liability | 5,265 | 3,702 |
| Operating lease liability, net of current | 34,794 | 39,001 |
| Total liabilities | 215,603 | 215,796 |
| Commitments and contingencies (Note 8) | ||
| Stockholders’ equity | ||
| Preferred stock, $0.0001 par value, 10,000,000 shares authorized | — | — |
| Common stock, $0.0001 par value; 500,000,000 shares authorized, 65,543,723 and 61,507,446 shares issued and outstanding as of December 31, 2025 and 2024, respectively | 7 | 6 |
| Additional paid-in capital | 714,090 | 664,874 |
| Accumulated other comprehensive loss | (3,827) | (3,356) |
| Accumulated deficit | (477,214) | (438,588) |
| Total stockholders’ equity | 233,056 | 222,936 |
| Total liabilities and stockholders’ equity | $448,659 | $438,732 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.